The presence of putative tumor-suppressor genes on chromosome 16q23.2-24.1 has been suggested by LOH analysis in several cancer types. This region overlaps with the fragile site FRA16D and the region of homozygous deletions found in several cancer types. The candidate gene WWOX/FOR has been mapped within this region. The mouse homologue of the WWOX protein has been de®ned as an apoptogenic protein and an essential partner of p53 in cell death, supporting WWOX as a tumor suppressor gene candidate. We performed an expression study of the WWOX/FOR gene in a series of human breast tumors and breast cancer cell lines, and detected reduced expression of the WWOX/ FOR transcript in a series of breast cancer cells. Furthermore, identi®cation of two distinct alternative WWOX transcripts expressed at high levels in human tumors suggests an involvement of the WWOX gene in breast cancer progression.
Introduction
The molecular mechanisms underlying breast cancer progression are still unclear, although it is believed to be a complex process involving a multi-step cascade of genetic events. Studies on recurrent somatic genetic alterations in human tumors have led to the identi®ca-tion of several`cancer genes' which have been suggested to be involved in the initiation and/or progression of breast cancer (Bieche and Lidereau, 1995) . One of the most frequent aberrations detected in breast cancer as well as in other cancers (hepatocellular carcinoma, ovarian and prostatic cancers, Wilms' tumors, myeloid malignancies and central nervous system primitive neuroectodermal tumors) is loss of heterozygosity (LOH) on the long arm of chromosome 16 (Tsuda et al., 1990; Sato et al., 1991; Latil et al., 1997; Grundy et al., 1998) .
In primary breast cancer, a high frequency of LOH on 16q (50 ± 55%) has been reported by several groups (Larsson et al., 1990; Takita et al., 1992; Lindblom et al., 1993; Cleton-Jansen et al., 1994; Deng et al., 1994; Tsuda et al., 1994; Dorion-Bonnet et al., 1995; Skirnisdottir et al., 1995) . At least three common regions of 16q LOH have been identi®ed in breast carcinomas: SRO1 on 16q24-qter; SRO2 on 16q22.1 (Cleton-Jansen et al., 1994; Dorion-Bonnet et al., 1995; Skirnisdottir et al., 1995) and SRO3 on 16q23.2-24.1 (Aldaz et al., 1995; Driouch et al., 1997) .
The region of LOH in 16q23.2-24.1 showed higher frequencies of alteration in distant metastases of breast and prostate cancers (Suzuki et al., 1996; Li et al., 1999) . Furthermore, it has been shown by microcell-mediated chromosome transfer that chromosome 16q23-24 is a strong suppressor of the metastatic activity of a prostatic cancer cell line (Mashimo et al., 1998) . All these results suggest the presence in this area of a major tumor suppressor gene associated to cancer progression.
Furthermore, several fragile sites are located on chromosome 16 (FRA16A on p13.11, FRA16B on q22.1, and FRA16C on q23.1). Common fragile sites might predispose to speci®c chromosomal breakage associated with deletion, ampli®cation, and/or translocation in certain forms of cancer (Shen et al., 1994) . This is the case for fragile site FRA3B and may be for FRA7G in several types of cancer . Recently, the fragile site FRA16D has been mapped to the 16q23.2 region coinciding with the region of homozygous deletions found in various cancers Paige et al., 2000) . In addition, FRA16D is bracketed by four translocation breakpoints involved in multiple myeloma (Chesi et al., 1998) . Taken together, these data suggest that FRA16D is overlapping a region containing a tumor suppressor gene.
In this study, we present a detailed physical map within the LOH region on human chromosome 16q23.2. Twelve cDNA clones corresponding either to single or clustered expressed sequence tags (ESTs) have been mapped to the region. Three of the cDNA clones contained sequences identical to the WWOX gene (also characterized as FOR gene: fragile site FRA16D oxidoreductase) (Bednarek et al., 2000; Ried et al., 2000; Paige et al., 2001) . A predominant and ubiquitously expressed full-length transcript (FOR II) and several alternative variants of the WWOX gene have been documented Paige et al., 2001) . Recently, Paige et al. demonstrated that homozygous deletions in the chromosome 16q23.2 region are aecting WWOX exons in various cancer cell lines. They also identi®ed a possible homozygous deletion in a primary ovarian tumor. These deletions result in frameshifts leading to shorter WWOX variants lacking part or all the ADH domains. These results suggest WWOX as a tumor suppressor gene in multiple tumor types.
Furthermore, the mouse homologue of the WWOX protein has been demonstrated to down-regulate the apoptosis inhibitors Bcl-2 and Bcl-xL and up-regulate the proapoptotic p53 (Chang et al., 2001) , also supporting the WWOX gene as a candidate tumor suppressor gene. We have revealed reduced expression of the full-length WWOX transcript in a series of breast tumors and breast cancer cell lines. In addition, variant transcripts encoding truncated proteins were frequently found in the breast tumor cell lines and tumor samples but only at low levels in one of the control samples from normal breast tissue. The detection of high levels of the alternative WWOX transcripts speci®cally in tumors indicates that WWOX may be involved in the breast cancer process.
Results

The SRO3
In order to construct a contig map spanning the commonly deleted region at chromosome 16q23, overgos derived from the microsatellite markers D16S3097, D16S3138, D16S3125 and D16S518 were pooled and used to screen the P1-derived arti®cial chromosome (PAC; Ioannou et al., 1994) libraries RPCI-5 and -6 (http://www.chori.org/bacpac). The initial contigs were extended and linked by three rounds of library screening using PAC end probes. The clones were digested with nine CpG cutters, separated by pulsed®eld gel electrophoresis (PFGE), and mapped in Southern blot experiments using probes from 14 PAC subclones and 12 ESTs, allowing the organization of a 1.2 Mb contig. A minimum tiling path consisting of 9 PACs covers the SRO3 region (Figure 1 ).
In order to identify genes within SRO3, we have used two complementary methods: mapping and subcloning of CpG islands, and EST screening. Since clusters of sites for CpG cutters are strong evidence for the presence of CpG islands and genes (Larsen et al., 1992) , we subcloned and sequenced fragments from the two putative CpG islands indicated in Figure 1 (GenBank accession no. AZ124369, AZ124375, AZ124377, and AZ124379). In addition, homology searches with the sequences obtained from the region allowed the identi®cation of 12 EST clones in the contig (Figure 1a) . The corresponding Image clones were obtained from HGMP-RC (Sanger Centre, UK) and their identities veri®ed by sequencing. The sequences of the ESTs and the CpG subclones were further used in homology searches in all available databases. One of the cDNA clones contained sequences identical to the KIAA1576 gene and three other cDNA clones contained sequences identical to the WWOX/FOR gene (Bednarek et al., 2000; Paige et al., 2001) .
Expression of WWOX mRNAs in human breast tumors
We analysed WWOX mRNA expression in four normal breast tissue samples, a pool of six normal human breast tissue samples (Clontech), nine breast cancer cell lines and 20 human breast tumor samples by RT ± PCR (Figure 2 ).
Reduced expression of the wild type WWOX transcript in tumor tissue and detection of an alternative variant Co-ampli®cation using the primer Wx-U3 in combination with Wx-L6' and Wx-L9 (Figure 3 ), resulted in three PCR products of dierent sizes.
In the normal breast tissue specimens, the primer pair Wx-U3/Wx-L9 yielded a major 1181 bp RT ± PCR fragment, which is the size predicted from the WWOX/ FOR II cDNA (GenBank accession no. AF211943 and AF227527). The 1181 bp fragment was also detected in eight out of the nine cell lines. In three of the cell lines, SK-BR-3, MDA-MB-231 and MDA-MB-361, a weak signal at the level of detection was obtained. A Northern blot of tumor cell line RNAs was hybridized with a WWOX coding region probe (Figure 2b ). This Northern blot con®rmed the reduced expression of the full-length transcript in the three above-mentioned cell lines compared to cell lines showing a 1181 bp WWOX fragment by PCR such as MCF7 and BT-20.
The 1181 bp fragment was also detected in all the human breast tumor samples except for T396. In this tumor sample, only an alternative 641 bp fragment was obtained. This smaller fragment was also ampli®ed as an additional fragment in the MCF-7 cell line and at a minor level in a few other tumors but in none of the normal samples tested (Figure 2a) .
The smaller transcript from the tumor T396 and the MCF-7 cell line was ampli®ed and sequenced revealing absence of exons 6, 7, and 8 sequence. This was con®rmed by PCR using a primer covering the exon 5 to 9 junction in the transcript (Wx-Ldel5-9: 5'-GCTCCCTGTTGCCATTCTTCTA-3', Figure 3 ). The absence of exons 6, 7 and 8 results in an in-frame loss of 180 amino acids including the conserved residues YXXXK and S, characteristic of the substrate binding site of the alcohol dehydrogenase domain (ADH domain) of the WWOX protein ( Figure 3 ). This transcript has also been observed in several cell lines and primary ovarian tumors carrying homozygous deletions within the WWOX gene (Paige et al., 2001 ; GenBank accession no. AF395123).
Increased expression of a short WWOX variant in tumor tissue compared to normal breast tissue A short WWOX cDNA variant, which contains the ®rst ®ve exons and an alternative exon 6 (exon 6') was identi®ed in database searches and recently characterized as the FOR III transcript GenBank accession no. AF187015 and AF227528) . In order to analyse the expression of this shorter mRNA species in our tumor samples, we designed the primer Wx-L6' (Figure 3 ). The primers Wx-U3/Wx-L6' detected the expected 361 bp fragment at a low level in the RNA pool from six normal human breast tissue samples, but not in the RNAs from four normal breast tissue samples from cancer patients (Figure 2a ).
In our series of tumor samples, the FOR III transcript was detected in 10 out of 20 tumors, and in eight out of nine of the cell lines analysed. High concentrations of the 361-bp fragment were detected in most of these samples. The resulting mRNA, which does not include the sequences of exons 6, 7, 8 and 9 encodes a protein of 189 amino acids lacking the majority of the WWOX ADH domain (Figure 3 ).
We analysed matched normal and primary tumor breast tissues from two patients using the Wx-U3/Wx-L6' primer pair (Patients 3079 and 4155; Figure 2a ). In tumor T4155, none of the shorter transcripts were detected. In contrast, the tumor T3079 showed high levels of the FOR III transcript, which was not detected in the matching normal tissue. (Frengen et al., 2000) are pre®xed with 6. The addresses of the nine PAC clones in the minimal tiling path contig are labeled in yellow. The BAC clones 11-571O6 (GenBank accession no. AC017112), 11-281J9 (GenBank accession no. AC010650) and 11-190D6 (GenBank accession no. AC009044) from the RPCI-11 library (Osoegawa et al., 2001) are included in the map based on sequence identity to the probes indicated with dashed lines. Filled circles indicate the T7 end of the PAC clones as determined by the hybridization with Sp6 and T7 oligonucleotides. Two CpG islands are indicated as green boxes in the map based on the presence of clusters of rare cutter restriction sites. Sites for the restriction enzymes AscI (A), BssHII (B), MluI (M), NruI (N), PvuI (P), and SacII (S), have been completely mapped in the contig. No NotI sites were found in any of the clones. Selected sites for EagI (E) are shown in the map high-lighting the CpG islands Alternative WWOX transcripts expressed in breast tumors K Driouch et al Smaller fragments are expected to be more eciently ampli®ed than larger fragments. The reliability of our molecular analysis was repeated in a real-time quantitative RT ± PCR assay based on¯uorescent TaqMan methodology. WWOX variants were quanti®ed in normal breast tissues and the tumors expressing the short variant. The real-time quantitative RT ± PCR results con®rmed that the tumors showed higher levels of the smaller transcript compared to the normal tissues (data not shown).
Analysis of the WWOX/FOR gene integrity in breast tumors
In order to determine whether the shorter WWOX transcripts detected are caused by genomic homozygous deletions as described in other cancer types (Paige et al., 2001) , we performed an analysis of the integrity of the WWOX gene in breast cancer cell lines and human tumors. DNA was available both from tumors and blood samples from 11 of the 20 tumors used in the present study. By using seven microsatellite markers, we screened eight cell lines and 11 tumor samples (Table 1) . At least one allele was detected with all the markers in all the cell lines and tumors analysed, giving no evidence of homozygous deletions involving any of the markers used (Table 1) .
In the cancer cell lines we observed increased hybridization signal of one of the two alleles of marker D16S516 only in BT-20. This LOH, which was identi®ed due to tumor cell heterogeneity of the breast cancer cell line, may indicate allelic imbalance of the D16S516 locus in intron eight of the WWOX gene.
None of the cell lines T-47D, SK-BR-3, MDA-MB-231 and MDA-MB-468 were heterozygous for the markers used. Since the informative rates of these microsatellite markers were higher than 0.63, detection of single alleles for more than ®ve adjacent markers strongly suggest monoclonal deletion of the region analysed (P50.003) (Latif et al., 1992) . In the same way, MCF-7, MDA-MB-157 and MDA-MB-435S are showing large regions of homozygosity not excluding the possibility of monoclonal deletions.
The LOH results showed that nine of 11 tumors exhibited at least one deleted marker in the WWOX Figure 2 Expression of the WWOX gene in breast cancer cell lines and human primary breast tumors. (a) WWOX cDNA was generated from nine breast cancer cell lines, one pooled normal breast, four normal breast (P) and 20 breast tumors (T). Primer pair Wx-U3/Wx-L9 was used to detect normal size WWOX cDNA (1181 bp), which was generated by RT ± PCR from transcripts present in normal tissues and most of the cancer cells. This primer set also yielded a smaller cDNA fragment (641 bp), which resulted from transcripts found preferentially in cancer cells. Primer pair Wx-U3/Wx-L6' generated a shorter cDNA fragment (361 bp) at high concentration in the majority of cell lines and tumors. The expression of TBP was examined as a positive control for cDNA synthesis. Lanes M1 and M2 contain molecular size standards 100 bp and 1 kb ladders, respectively (Genaxis, Woburn, MA, USA). (b) Northern blot analysis of WWOX expression in breast cancer cell lines. RNA extracted from 10 6 cells was blotted and hybridized with a PCR fragment corresponding to exons 2 ± 5 in the WWOX cDNA (152-628 in GenBank accession no. AF211943). The blot was also hybridized with a GAPDH probe as a control (bottom panel)
Oncogene Alternative WWOX transcripts expressed in breast tumors K Driouch et al region (Table 1) . However, no clear correlation was observed between the occurrence of genomic alterations and the variation in the WWOX/FOR expression pattern. Among the tumors with predominant expression of the full-length WWOX transcript, some showed LOH in the WWOX gene (see sample T283) while in others no LOH was detected (see sample T256). In the same way, shorter WWOX transcripts were observed both among the tumors where no LOH was detected and in tumors showing LOH (compare sample T150 and T517).
In tumor T396, which expresses the shorter mRNA lacking the sequences from WWOX exons 6 to 8, a short interstitial deletion at the end of intron 5 (marker AFMA336yg9) was detected. In order to explore the possibility of a homozygous deletion of exons 6 ± 8 in this tumor, PCR primers were designed to amplify each of the nine exons. The fragments ampli®ed were shown to contain the expected sequences. This result does not support homozygous deletion of exons 6, 7 and 8 in tumor T396 (data not shown). Furthermore, no mutations were found in the exons or in the exonintron boundaries of exon 5 to 9 (data not shown). These results suggest that the presence of variant WWOX transcripts in breast tumors might be due to a combination of both genetic alterations and transcriptional events.
Discussion
The region of deletion on 16q23 frequently observed in breast cancer has been identi®ed by our group and others (Larsson et al., 1990; Takita et al., 1992; Lindblom et al., 1993; Cleton-Jansen et al., 1994; Deng et al., 1994; Tsuda et al., 1994; Dorion-Bonnet et al., 1995; Skirnisdottir et al., 1995; Aldaz et al., 1995; Driouch et al., 1997) . Microsatellite markers D16S515 and D16S516 bracket this region and the most aected marker is D16S518 . A contig map consisting of 43 large insert clones was constructed covering a region of 1.2 Mb including the marker D16S518.
Chromosome 16q23 LOH has been described in a range of cancer types (Tsuda et al., 1990; Sato et al., 1991; Latil et al., 1997; Grundy et al., 1998) . We previously reported high frequencies of deletions within 16q23 in human breast carcinomas, both in primary tumors (61%), local recurrences (62%) and distant metastases (83%) (Driouch et al., 1998) . In a study of 59 samples from prostate cancer patients, we also found high incidence of deletion on chromosome 16q23-q24 (Latil et al., 1997) . High frequencies of deletions in the 16q23-24 region have also been detected in metastases of prostate cancers (Suzuki et al., 1996; Elo et al., 1997; Li et al., 1999) , and this Figure 3 A graphical presentation of the WWOX gene, the transcripts detected and corresponding deduced protein variants. The primers Wx-U3, Wx-L6', Wx-L9, and Wx-Ldel5-9 used for RT ± PCR are shown as arrows. The alternative exon 6' is shown as a red box. ww=WW domains, c=coenzyme binding motif, and s=substrate binding motif chromosomal region has been shown to suppress the metastatic ability of rat prostatic cell lines (Mashimo et al., 1998) . Moreover, homozygous deletions at 16q23.2 have been identi®ed in malignant ovarian ascites, in an ovarian tumor cell line, a colon carcinoma cell line, two small cell lung cancer cell lines, and a gastric adenocarcinoma cell line (Watson et al., 1999; Mangelsdorf et al., 2000; Paige et al., 2000 Paige et al., , 2001 . A common region of homozygous deletion of 270 kb has been sequenced, coinciding with the fragile site FRA16D Mangelsdorf et al., 2000; Krummel et al., 2000) . These results strongly suggest the presence of a suppressor gene involved in tumor progression on 16q23. In the present map, we identi®ed the two genes KIAA1576 and WWOX. Both these genes are encoding proteins containing alcohol dehydrogenase domains. KIAA1576 is a member of the zinc-binding dehydrogenase family whereas the WWOX gene belongs to the short-chain dehydrogenase family.
Since the fragile site FRA16D and the region of homozygous deletion are not involving the KIAA1576 gene, the WWOX/FOR gene appears to be the principal genetic target for DNA instability at FRA16D. Perturbation of the WWOX/FOR function is likely to contribute to the biological consequences of chromosome 16q23.2 instability in cancer cells Paige et al., 2001) .
The expression analysis of the WWOX gene in the present work showed reduced levels of the full-length (FOR II) mRNA in cancer cells. In addition, alternative WWOX mRNA species were frequently detected both in breast cancer cell lines and human tumors. Moreover, one short mRNA variant was the only WWOX transcript detected in one of the tumor samples. This variant was also detected at lower levels in other tumors, in a mixed expression pro®le together with the full-length transcript. The shorter WWOX mRNA encodes a truncated protein of 234 amino acids due to the lack of exons 6, 7 and 8. This WWOXdelta6-8 variant has also been reported in several homozygously deleted cell lines and primary ovarian tumors (Paige et al., 2001) . The heterozygous status of the majority of the tumors expressing this variant in the current work is suggesting that this transcript is likely to result from RNA processing. However, this WWOX variant was not detected either in the normal cDNAs tested in this study or in the normal ovarian RNAs analysed by Paige et al. (2001) , suggesting that the WWOXdelta6-8 alternative transcript may be cancer associated.
In addition to the WWOXdelta6-8 mRNA variant, we also detected high expression of another mRNA, FOR III, in 50% of the tumors. The FOR III transcript, which was also present at a low level in one of the normal breast tissue samples, contains the sequences from the ®rst ®ve exons and an alternative exon 6'. The expression pro®les of two additional alternative transcripts, FOR I and FOR IV, have also been analysed. These transcripts were detected at low levels both in the breast cancer samples and the normal breast tissue samples (data not shown).
Since the inactivation of tumor suppressor genes is recessive, two distinct mutational events are usually required. In sporadic cancers, one event is often the LOH, and the other allele could be altered by a dierent mutational event, such as point mutations, deletions, rearrangements and hypermethylations. In a recent study, Bednarek et al. (2000) performed a mutation screening of the coding region of the WWOX gene in a panel of 27 breast cancer cell lines, and reported no evidence of point mutations within the nine exons of the WWOX gene. However, one cell line showed a homozygous deletion spanning a part of WWOX intron 8 (Bednarek et al., 2000) . We have analysed the integrity of the WWOX gene in tumor T396. No mutation was detected in the coding regions and the exon-intron junctions in this tumor, suggesting that the intermediate transcript lacking exons 6 to 8 identi®ed in this tumor might be a result of a transcriptional event.
Homozygous deletions within the WWOX gene have previously been demonstrated in various cancer types Paige et al., 2000 Paige et al., , 2001 Ried et al., 2000) . We did not detect any homozygous deletions either in the breast tumors or in the breast cancer cell lines tested. In addition, all the breast cancer cell lines used in the present study have previously been shown by cytogenetic analysis to contain at least one normal chromosome 16 (Davidson et al., 2000) . Even though we obtained an indication for an intragenic LOH in one of the cell lines analysed, this alteration is not expected to be sucient to explain the altered WWOX gene expression observed. Therefore, further investigations on the integrity of the gene and its transcription regulation would be of great interest.
Recently, the murine WOX1 protein was characterized (Chang et al., 2001) , showing 93% identity with the human WWOX/FOR protein. The mouse protein is mainly located in the mitochondria, and the induction of mitochondrial permeability results in WOX1 nuclear translocation. It has been shown that WOX1 enhances TNF cytotoxicity by down regulating the apoptosis inhibitors Bcl-2 and Bcl-xL and up regulating the proapoptotic p53. When over expressed, the ADH domain (but not the WW domains) of WOX1 mediated apoptosis, probably due to modulation of expression of these proteins (Chang et al., 2001) . Furthermore, WW domains are known to interact with other proteins. The WW domains of the mouse WOX1 protein were shown to bind to the proline-rich region of p53. These data strongly suggest that there is a partnership between p53 and WOX1. However, WOX1-mediated apoptosis appeared to be independent of p53, but p53 induced apoptosis seemed to require the participation of WOX1. Therefore, the WOX1 protein was de®ned as an apoptogenic protein and an essential partner of p53 in cell death (Chang et al., 2001) .
Since the human and murine proteins are highly similar, it is tempting to suggest that the human WWOX/FOR is also involved in apoptosis. We detected increased expression of two short WWOX mRNA variants in tumors samples. The major part of the ADH domain in the WWOX protein, including the substrate binding motifs, is deleted in proteins encoded by these transcripts. This loss of the ADH domain could impair the mechanisms required for the regulation of apoptosis. Furthermore, if WWOX binds to p53, and the function of p53 requires the presence of the normal WWOX, then the alteration in WWOX expression in cancer cells would be a major event in tumor progression.
Our results suggest that WWOX may be a tumor suppressor gene involved in breast cancer. The investigation of large series of breast and prostate cancers as well as series of secondary tumors from these cancers would be a starting point for con®rming the role of WWOX protein in the initiation and progression of these cancers. Furthermore, functional studies of WWOX/FOR in human cells would allow a better characterization of the speci®c role of the WWOX protein in human cancer.
Materials and methods
Samples
We analysed tissue from excised primary breast tumors of 20 women treated at the Centre ReneÂ Huguenin before 1990. The samples were examined histologically for the presence of tumor cells. Each tumor sample was considered suitable for this study when the proportion of tumor cells was more than 60%. Immediately following surgery, the tumor samples were stored in liquid nitrogen until the recent RNA extraction.
The patients (mean age 58.3 years, range 34 ± 91) met the following criteria: primary unilateral non-metastatic breast tumors and no radiotherapy or chemotherapy before surgery.
We also analysed nine breast tumor cell lines obtained from the American Tissue Type Culture Collection (T-47D, MCF-7, BT-20, SK-BR-3, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-435S and MDA-MB-468).
Specimens of normal breast tissue from four of the breast cancer patients were used as sources of normal RNA. In addition, total RNA from a pool of six normal human breast tissue samples was purchased from Clontech (Palo Alto, CA, USA).
Expression analysis
Total RNA from four normal breast tissue samples, nine breast tumor cell lines and 20 human breast tumors was extracted using the acid-phenol guanidinium method (Chomczynski and Sacchi, 1987) . The quality of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide. The yield was quanti®ed spectrophotometrically in a 50 ml microcuvette.
RNA was reverse transcribed in a ®nal volume of 20 ml containing RT ± PCR buer (1 mM each dNTP, 5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.3), 20 units of RNase inhibitor (Perkin Elmer, Foster City, CA, USA), 50 units of Moloney Murine Leukemia Virus reverse transcriptase (Perkin Elmer), 2.5 mM random hexamers and 1 mg of total RNA. The samples were incubated at 208C for 10 min and 428C for 30 min, and reverse transcriptase was inactivated by heating at 998C for 5 min and cooling at 58C for 5 min. The volume was then made up to 200 ml with Alternative WWOX transcripts expressed in breast tumors K Driouch et al RT ± PCR buer, yielding the RT mix used for PCR. Ten microliters (1/20 of RT-mix) was used for subsequent PCR.
To assess the precise amount of total RNA added to each reaction, we quanti®ed the transcripts of TBP (a component of the transcription factor complex TFIID) as the endogenous mRNA control, and each sample was normalized on the basis of its TBP content (there are no known TBP retropseudogenes) (Bieche and Lidereau, 1999) . Primer pairs for RT ± PCR were chosen using the Oligo 4.0 (National Biosciences) computer program and by performing BLASTN searches.
For each PCR run, a master mix was prepared on ice with 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.3 and one unit of AmpliTaq Gold DNA polymerase (Perkin Elmer). The expression of the WWOX gene was analysed by a coampli®ca-tion using three primers (Figure 3) . One common upper primer (Wx-U3: 5'-CGGATGGGAACAAGAAACTGAT-GA-3', 400 nM) and two distinct lower primers (Wx-L9: 5'-TTTCCTTTACTCTTGCGGATCTGTG-3', 300 nM and Wx-L6': 5'-TTCTGGCGGAGGGTGGTATTTTG-3', 100 nM) were used. Ten microliters of RT-mix for each sample was added to 40 ml of the master mix on ice. The PCR consisted of an initial denaturation step at 948C for 10 min and 35 cycles of 1 min at 948C, 1 min at 608C, 1 min 30 s at 728C, and a ®nal extension step of 10 min at 728C, using a Perkin-Elmer 9600 DNA thermocycler.
Northern blots containing RNA extracted from 10 6 cells from each of six breast tumor cell lines were hybridized with a WWOX cDNA fragment that was produced by PCR ampli®cation using primers WP1: 5'-GGACGACACGGA-CAGTGAG-3' and WP2: 5'-ATGCGTGACACTGCTT-CACT-3'. Prehybridization and hybridization were performed in ExpressHyb TM solution (CLONTECH). A complete cDNA was used to generate a probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The ®lters were scanned on STORM 860.
Assessing the WWOX gene structure DNA was extracted from leukocytes and tumors from 11 patients and from eight cell lines using standard methods. We analysed seven microsatellite markers spanning the region containing the WWOX/FOR gene (Table 1) . These markers were ®rst analysed by multiplex PCR. Then all the LOH patterns were veri®ed by standard PCR. The PCR products were loaded on 6% acrylamide gel containing 7.5 M urea. The hybridizations of the nylon ®lters were carried out with a radiolabeled oligonucleotide (CA repeat).
Abbreviations LOH, loss of heterozygosity; PAC, P1-derived arti®cial chromosome; EST, expressed sequence tag; ADH, alcohol dehydrogenase
